As previously reported, RBC Capital analyst Simos Simeonidis upgraded Sarepta Therapeutics to Outperform from Sector Perform, stating that he "just can't see" the FDA not approving eteplirsen. Simeonidis, who said that acceptance of an NDA for review by the FDA is usually "little more than a formality," believes that the case is different for Sarepta, for whom he thinks the acceptance of the file is a very positive signal for the DMD drug's eventual chances for approval. The analyst raised his price target to $62 from $35 on Sarepta shares, which are up about 3.6% to $33.75 in pre-market trading.